Hims & Hers FDA Warning Over Deceptive GLP-1 Marketing

Late last year, the Food and Drug Administration (FDA) issued a formal warning to Hims & Hers Health over marketing practices involving GLP-1 weight loss medications. The agency found that certain promotional materials created the impression that compounded GLP-1 drugs were the same as FDA-approved medications such as semaglutide or tirzepatide. According to regulators, this type of messaging is misleading and could cause consumers to believe they were receiving fully reviewed and approved drugs when that was not the case.

GLP-1 medications were originally developed to treat type-2 diabetes and obesity and went through extensive clinical trials before being approved. Due to overwhelming demand and supply shortages, many telehealth platforms began offering compounded versions through partner pharmacies. These compounded drugs are not reviewed by the FDA for safety, strength, or effectiveness in the same way as branded medications. When companies blur that distinction in advertising, it raises serious legal and patient safety concerns.

What the FDA Objected to in the Hims & Hers Marketing

The FDA’s warning for Hims & Hers focused on how compounded GLP-1 products were being promoted. Marketing language implied that patients were receiving the same drugs used in major clinical trials, without clearly disclosing that these were non-approved compounded versions. This matters because federal law prohibits advertising drugs in a way that is false or misleading.

Regulators emphasized that companies must clearly communicate when a product is not FDA-approved and cannot claim clinical benefits associated with approved drugs unless supported by proper evidence. Failing to do so may result in enforcement actions and potential liability under consumer protection laws.

Why the Hims & Hers GLP-1 Marketing Is Dangerous

When patients rely on misleading information, they may make treatment decisions without understanding the real risks. Compounded drugs may vary in potency and purity, and side effects may not be tracked as closely as they are for approved medications. If something goes wrong, patients may not have the same safety data available to guide medical responses.

This kind of marketing also undermines public trust in healthcare systems and telehealth platforms. Consumers expect transparency, especially when dealing with prescription medications and weight-loss treatments that affect long-term health.

Potential Legal Claims for Consumers

When companies market drugs in a deceptive manner, affected individuals may have legal rights under state consumer protection laws and unfair competition statutes. If a person relied on misleading advertising and suffered harm, they may be able to pursue claims for misrepresentation, negligence, or violations of deceptive trade practice laws.

Damages in these cases may include medical expenses, refunds for products purchased under false pretenses, lost wages, emotional distress, and other financial losses. In some situations, these cases proceed as class actions when large groups of consumers were affected by the same conduct.

Why Hire The Lyon Firm for Deceptive Drug Marketing Cases

The Lyon Firm represents individuals harmed by misleading pharmaceutical and health product marketing. Our firm focuses on cases where companies fail to disclose important safety information or promote drugs in a way that distorts the truth.

The Lyon Firm can help clients understand how deceptive GLP-1 marketing may have impacted their treatment decisions, evaluate whether legal violations occurred, and pursue compensation where appropriate. Our attorneys work with medical and regulatory experts to analyze how marketing practices affected patient safety and financial harm.

The Lyon Firm offers free and confidential consultations and handles cases on a contingency basis, meaning clients pay nothing unless compensation is recovered.

––––––––––––––––––––––

• Why did the FDA warn Hims & Hers about GLP-1 drugs? The FDA warned the company because its marketing implied that compounded GLP-1 drugs were the same as FDA-approved medications. The agency said this could mislead consumers into believing they were receiving fully reviewed and regulated treatments.
• What are compounded GLP-1 medications? Compounded GLP-1 drugs are custom-mixed versions of medications like semaglutide or tirzepatide made by pharmacies. These products are not reviewed by the FDA for safety, strength, or effectiveness the way branded drugs are.
• Why is deceptive GLP-1 marketing dangerous? Patients may rely on misleading claims when choosing treatment. If a drug is not FDA-approved but is marketed as if it is, consumers may not understand the risks, side effects, or lack of testing involved.
• Can consumers sue over misleading GLP-1 advertising? Yes. If someone relied on deceptive marketing and suffered financial loss or medical harm, they may have legal claims under consumer protection and misrepresentation laws.
• What damages can be recovered in deceptive drug cases? Depending on the situation, damages may include medical bills, lost wages, out-of-pocket costs, emotional distress, and sometimes punitive damages for willful misconduct.
• Who should contact a lawyer about the GLP-1 issue? Anyone who used compounded GLP-1 drugs through telehealth platforms and believed they were FDA-approved, or anyone who suffered side effects or financial loss, should speak with an attorney.